PepGen Inc.

PepGen Inc.

PEPG·NASDAQ

$1.46

+3.0%
HealthcareBiotechnology

PepGen Inc., a clinical-stage biotechnology company, focuses on the development of oligonucleotide therapeutics for use in the treatment of severe neuromuscular and neurologic diseases. The company's lead product candidate is PGN-EDO51, an EDO peptide in Phase I clinical trials to treat individuals with Duchenne muscular dystrophy (DMD). It is also developing PGN-EDODM1, an EDO peptide-conjugated PMO for the treatment of myotonic dystrophy type 1, as well as EDO therapeutic candidates, such as PGN-EDO53, PGN-EDO45, and PGN-EDO44 for the treatment of DMD. The company was founded in 2018 and is headquartered in Cambridge, Massachusetts.

At a Glance

Live Snapshot
Market Cap$101.28M
EPS-2.1200
P/E Ratio-0.69
Earnings Date08/06/2026

pepg

Cash and Short Term Investments

Last Annual Value

148.46M

3-Year CAGR

-7%

5-Year CAGR

72%

10-Year CAGR

46%

PepGen Inc.

PepGen Inc. Competitors Analysis of Cash and Short Term Investments

PEPG · NASDAQ
CompanyCash and Short Term Investments
CAGR 3Y
CAGR 5Y
CAGR 10Y
PEPG logo
PepGen Inc.
NASDAQ:PEPG
148.46M
10.4%2.2%N/A 
ALEC logo
Alector, Inc.
NASDAQ:ALEC
256.02M
-22.4%-19.0%17.5%
NKTX logo
Nkarta, Inc.
NASDAQ:NKTX
276.28M
3.6%3.0%N/A
79.40M
16.7%-0.4%N/A
13.16M
64.5%N/AN/A
176.48M
28.8%47.0%N/A
248.54M
-0.7%-4.3%N/A
31.63M
18.3%40.7%N/A
76.13M
-20.3%-30.0%N/A
95.50M
-7.6%-16.4%17.7%
163.94M
98.7%10.9%27.0%
PepGen Inc.

PepGen Inc. Fair Value Envelope

PEPG · NASDAQ

Our analysis suggests that PEPG has a fair value of HIDDEN per share in the Base Case projection. With shares currently trading at $1.4642, this represents a potential HIDDEN relative to our calculated worth for PepGen Inc..

Intrinsic Value
Current Price: $1.4642